Nairobi — UK drugmaker GlaxoSmithKline Limited (GSK) has rebranded to Haleon Kenya Limited, effective March 14, 2025. The rebrand comes after GSK transferred its consumer health business to Haleon to ...

Getting a headache and feeling sick are common side-effects for many medicines. Indulging in risky sexual behavior or ...

Prevalence rates of what GSK calls "deviant" sexual behaviours caused by the drugs are unknown and tend to be under-reported ...

In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against other best weight ... starting with ...

Glaxo (GSK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

The deal includes two recently approved GSK products for metastatic melanoma ... lucrative and growing sectors in the industry. The UK-headquartered firm says this part of the deal represents ...

Getting a headache and feeling sick are common side-effects for many medicines. Indulging in risky sexual behaviour or pathological gambling – not so common. But a BBC investigation has highlighted ...

UK drugmaker GSK is struggling to convince the market ... said investors were confident about the company’s ability to commercialise products, but saw its research and development as more ...

Despite early success, Verona's lack of specific 2025 guidance and competition from Dupixent and other drugs raise concerns.